Literature DB >> 19545852

Review and update: current treatment trends for patients with retinitis pigmentosa.

Kelly Shintani1, Diana L Shechtman, Andrew S Gurwood.   

Abstract

BACKGROUND: Retinitis pigmentosa (RP) is a heterogeneous group of inherited retinal disorders characterized by progressive photoreceptor apoptosis. It is the leading cause of inherited retinal degeneration-associated blindness. RP has a unique set of clinical characteristics that make it a complex disease associated with distinct inheritance patterns. An understanding of the pathogenesis is essential in the process of the differential diagnosis and the development of treatment options. Recent developments in research are likely to expand the various therapeutic modalities to include gene therapy, pharmacologic treatment, cell transplantation, and neuro-prosthetic devices.
METHODS: A literature search was performed to comprehensively review RP diagnosis, pathophysiology, and treatment.
CONCLUSION: Advances in the understanding of the pathophysiology of RP are creating new opportunities for the treatment of this often visually debilitating eye condition. Optometrists, as primary eye care practitioners, should be aware of the inheritance, pathophysiology, and current treatment options for RP as well as treatments in development so that they can best care for their patients with inherited retinal disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19545852     DOI: 10.1016/j.optm.2008.01.026

Source DB:  PubMed          Journal:  Optometry        ISSN: 1558-1527


  64 in total

Review 1.  Nanoparticles for retinal gene therapy.

Authors:  Shannon M Conley; Muna I Naash
Journal:  Prog Retin Eye Res       Date:  2010-05-07       Impact factor: 21.198

Review 2.  Retinal pigment epithelium differentiation of stem cells: current status and challenges.

Authors:  Basak E Uygun; Nripen Sharma; Martin Yarmush
Journal:  Crit Rev Biomed Eng       Date:  2009

Review 3.  Cilia in cell signaling and human disorders.

Authors:  Neil A Duldulao; Jade Li; Zhaoxia Sun
Journal:  Protein Cell       Date:  2010-08-28       Impact factor: 14.870

4.  Seeing through their eyes: lived experiences of people with retinitis pigmentosa.

Authors:  M Prem Senthil; J Khadka; K Pesudovs
Journal:  Eye (Lond)       Date:  2017-01-13       Impact factor: 3.775

Review 5.  Regenerative therapies for central nervous system diseases: a biomaterials approach.

Authors:  Roger Y Tam; Tobias Fuehrmann; Nikolaos Mitrousis; Molly S Shoichet
Journal:  Neuropsychopharmacology       Date:  2013-09-04       Impact factor: 7.853

6.  Optogenetic Retinal Gene Therapy with the Light Gated GPCR Vertebrate Rhodopsin.

Authors:  Benjamin M Gaub; Michael H Berry; Meike Visel; Amy Holt; Ehud Y Isacoff; John G Flannery
Journal:  Methods Mol Biol       Date:  2018

7.  Retinal blood flow velocity measured by retinal function imaging in retinitis pigmentosa.

Authors:  Sven C Beutelspacher; Nermin Serbecic; Hila Barash; Zvia Burgansky-Eliash; Amiram Grinvald; Hermann Krastel; Jost B Jonas
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-08-27       Impact factor: 3.117

8.  Restoration of visual function by expression of a light-gated mammalian ion channel in retinal ganglion cells or ON-bipolar cells.

Authors:  Benjamin M Gaub; Michael H Berry; Amy E Holt; Andreas Reiner; Michael A Kienzler; Natalia Dolgova; Sergei Nikonov; Gustavo D Aguirre; William A Beltran; John G Flannery; Ehud Y Isacoff
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

Review 9.  Constitutively active rhodopsin and retinal disease.

Authors:  Paul Shin-Hyun Park
Journal:  Adv Pharmacol       Date:  2014

10.  N-methyl-N-nitrosourea-induced retinal degeneration in mice is independent of the p53 gene.

Authors:  Katsuhiko Yoshizawa; Maki Kuwata; Ayako Kawanaka; Norihisa Uehara; Takashi Yuri; Airo Tsubura
Journal:  Mol Vis       Date:  2009-12-30       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.